Sphere Fluidics raises £30m in Series B funding to accelerate international sales and product development.
The investment round was co-led by Sofinnova Partners and Redmile Group to fund global expansion and research programmes.
Sphere Fluidics develops and commercialises single cell analysis systems powered by proprietary picodroplet technology. The company supports global biotherapeutic discovery and development through its automated platforms.
Sphere Fluidics has secured £30m in Series B funding from Sofinnova Partners and Redmile Group. The capital will support the company as it expands international sales operations and customer service capabilities. Additional funds are earmarked for research and development initiatives, including new applications for the Cyto-Mine platform.
From the founder
"This is a transformational investment from two of the most respected specialist investment funds in the industry and a recognition of the untapped potential of the pioneering product and market development carried out by the Company to date"
Andrew Mackintosh
Chairman at Sphere Fluidics
Investor perspective
"We remain impressed by Cyto-Mine’s high-throughput, ease-of-use and accessible cost. In the growing markets of monoclonal antibody discovery, cell line development and cell therapy, we see a significant need for such an affordable and reliable single cell analysis system as Cyto-Mine, capable of performing multiple assays on tens of millions of individual cells per run."
Tom Burt
Partner, Sofinnova Partners
Use of funds
- 01Expand into international markets
- 02Fund research and development
Investors
Categories
About the company
Sphere Fluidics
Sphere Fluidics creates advanced single cell analysis systems for biotherapeutic discovery.